SCHEMBL1710380

SCHEMBL1710380

CC(C)(C)N1CC[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](NC(=O)O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2694200 1.00
SCHEMBL2244743 0.74 ATM (0.32)
SCHEMBL2691333 0.74 SSTR4 (0.35)
SCHEMBL2691929 0.74 SSTR4 (0.35)
SCHEMBL4444047 0.74 SSTR4 (0.35)
SCHEMBL1710171 0.73 CTSK (0.39)
SCHEMBL1710341 0.73 USP30 (0.31)
SCHEMBL1710387 0.73 USP30 (0.31)
SCHEMBL3384867 0.73 HTR4 (0.33)
SCHEMBL3384871 0.73 HTR4 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 US disclosed
US-20110195956-A1 Heterocyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
US-20110195980-A1 Bicyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
EP-2344473-A1 HETEROCYCLIC PIM-KINASE INHIBITORS Novartis AG (CH) 2011-07-20 EP disclosed
EP-2342190-A1 BICYCLIC KINASE INHIBITORS Novartis AG (CH) 2011-07-13 EP disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed